STALICLA SA | MedPath

STALICLA Appoints Dr. Paulo Fontoura as Chief Scientific and Clinical Development Advisor

8 months ago

• STALICLA SA has appointed Dr. Paulo Fontoura as Chief Scientific and Clinical Development Advisor to enhance its precision medicine approach for neurodevelopmental disorders. • Dr. Fontoura's extensive experience in CNS drug development, including work on multiple sclerosis and Alzheimer's, will support STALICLA's clinical programs. • STALICLA is advancing two Phase 2 clinical trials in autism spectrum disorder subgroups, with expected readouts within the next 24 months. • The company's lead asset, STP1, and another NDD asset are set to enter Phase 2 trials, while STP7 (Mavoglurant) is being advanced for Phase 3 trials.